Newsletter No. 86 -- April 2006
NIH - New Funding Initiatives1. QUICK-TRIALS FOR IMAGING AND IMAGE-GUIDED INTERVENTIONS: EXPLORATORY GRANTS (R21) (PAR-06-293) (NCI)
2. SOLICITATION OF ASSAYS FOR HIGH THROUGHPUT SCREENING (HTS) IN THE MOLECULAR LIBRARIES SCREENING CENTERS NETWORK (X01) (PAR-06-259)
Letters of Intent Receipt Date(s): April 20, Aug 16, Dec 20, 2006; Apr 20 and Aug 16, 2007
Application Submission Date(s): May 18, Sep 14, 2006; Jan 18, May 18, and Sep 14, 2007
The purpose is to invite investigators to seek access for their HTS assays to the Molecular Libraries Screening Centers Network (MLSCN), which intends to screen 100-200 HTS assays per year to fully utilize the capacity of the screening centers network.
3. UNDERSTANDING THE EFFECTS OF EMERGING CELLULAR, MOLECULAR, AND GENOMIC TECHNOLOGIES ON CANCER HEALTH CARE DELIVERY (R01) (PA-06-280) & (R21) (PA-06-281) (NCI)
The purpose is to invite applications for health services research addressing utilization of cellular, molecular, and genetic or genomic (CMG) technologies in cancer care. The studies will assess CMG technologies in relation to: quality of care; organizational barriers and change factors in utilization; cost and cost-effectiveness; disparities in access and efficacy; monitoring of cross-sectional patterns of care and time trends; impact on existing standards of care, and; influence on cancer outcomes such as incidence, progression, mortality, survival, and quality of life. This funding opportunity specifically encourages research on commercially available CMG clinical tools already in use, as well as experimental tools in the later stages of development and/or in the regulatory approval pipeline.
R01 URL: http://grants.nih.gov/grants/guide/pa-files/PA-06-280.html
R21 URL: http://grants.nih.gov/grants/guide/pa-files/PA-06-281.html
4. ETIOLOGY, PREVENTION, AND TREATMENT OF HEPATOCELLULAR CARCINOMA (R21) (PA-06-295) (NCI, NIAAA, NIBIB, NIDDK)
The several institutes are interested in receiving grant applications that address the etiology and etiologic mechanisms of hepatocellular carcinoma (HCC) and development of animal models, novel approaches to prevent this malignancy, and therapeutic or diagnostic studies aimed at establishing reliable prognostic indicators for disease progression and/or minimizing morbidity and mortality associated with this malignancy.
The objective of this FOA is to encourage grant applications for exploratory (R21) grants from individuals who are interested in testing new ideas that may advance progress in cancer detection, diagnosis, and prognosis. Imaging studies are not intended to be funding under this initiative. For imaging initiatives, call the Cancer Imaging Program staff.
6. PILOT STUDIES IN PANCREATIC CANCER (R03) (PA-06-314) (NCI) This funding opportunity is intended to promote innovative research across multiple disciplines for better understanding of the biology, etiology, detection, prevention, and treatment of pancreatic cancer.
7. CANCER PREVENTION RESEARCH SMALL GRANT PROGRAM (R03)(PAR-06-313) (NCI)
Application Receipt/Submission Date(s): July 20, 2006; November 20, 2006; March 20, 2007; July 21, 2007; December 20, 2007
The Division of Cancer Prevention of the NCI invites applications that address developmental research in chemoprevention agent development, biomarkers, early detection, and nutrition science. However, it is important to note that this funding opportunity does not include applications that are focused on treatment, etiology, or treatment-related quality of life studies that are population based. This Small Grants Program is designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of research expertise in cancer prevention research. It is anticipated that this Small Grant Program may lead to the submission of subsequent individual research project grants (R01).
8. IMAGING - SCIENCE TRACK AWARD FOR RESEARCH TRANSITION (I/START) (R03) (PAR-06-311) (NIDA)
This Funding Opportunity Announcement (FOA) issued by the NIDA is intended to facilitate the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs.
9. NEUROTECHNOLOGY RESEARCH, DEVELOPMENT, AND ENHANCEMENT (R21) (PA-06-278) & (R01) (PA-06-279) (NIMH, NIA, NIBIB, NICHD, NIDA, NIDCD, NIDDK, NINDS)
The purpose of this Funding Opportunity Announcement (FOA) is to encourage submission of new Exploratory/Developmental (R21) grant applications to research and develop innovative technologies, methodologies, or instrumentation for basic or clinical studies of the brain or behavior in human or non-human animals. Also solicited are applications for support to research, develop, and significantly enhance existing technologies that are important to understanding the brain or behavior.
R21 URL: http://grants.nih.gov/grants/guide/pa-files/PA-06-278.html
R01 URL: http://grants.nih.gov/grants/guide/pa-files/PA-06-279.html
10. RADIONUCLIDE DECORPORATION AGENTS FOR RADIATION/NUCLEAR EMERGENCIES: PROJECT BIOSHIELD (R01) (RFA-AI-06-030) (NIAID)
Application Receipt Date(s): May 15, 2006
This is a funding opportunity announcement (FOA) to accelerate the development of safe and effective products to remove radionuclides from the body (decorporation) following nuclear contamination from any source. Specifically, candidate products will demonstrate an increase in efficiency and rate of radionuclide elimination from the body after contamination due to ingestion, inhalation or transdermal absorption.
NIH Announces Change in Business Process: Replacing Principal Investigator Signature on Grant Applications, Progress Reports, and Prior Approval Requests with an Institutional Compliance Requirement (NOT-OD-06-054)
NIH/AHRQ Announce Change in Business Process Concerning eRA Commons Verifications of Electronically Submitted Applications (NOT-OD-06-055) URL: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-06-055.html
NIH Announces Interim Changes to the PHS398 Application and Instructions (NOT-OD-06-056)
NIH Announces Changes to the SF424 (R&R) Instructions (NOT-OD-06-057)
NIH Announces Interim Changes to the PHS2590 Noncompeting Progress Report Forms and Instructions (NOT-OD-06-058)
SCIENTIFIC CURATOR - NIH IMAGING AGENT DATABASE
Computercraft seeks an experienced imaging scientist to provide curatorial responsibilities for implementing and maintaining the NIH imaging agent database. The individual will work with NIH staff scientists and extramural advisors onsite at the NIH campus. Join our team of highly skilled and dedicated professionals as we participate in the development of a new centralized database of in vivo imaging agents. This innovative database will include agents developed for position-emission tomography (PET), single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), ultrasound and optical imaging. The database will be located within the National Center for Biotechnology Information (NCBI) at the National Institutes of Health (NIH). This diversified and challenging position requires a Ph.D. (strongly preferred) or M.S. degree in imaging sciences or highly related field. The successful candidate will have a demonstrable knowledge of the chemistry and developmental process of in vivo imaging agents, experience with current analytical tools in both chemistry and biology, and a working knowledge of the issues associated with the information technology and cheminformatics required to successfully implement this database. The ability to extract and summarize scientific information in a textual format is essential. Contact Computercraft for details.
Fax: (301) 493-1288
Mail: Computercraft, Attn: HR, 6701 Democracy Blvd.,Suite 401, Bethesda, MD 20817
Interagency Council on Biomedical Iimaging in Oncology Meeting
The next ICBIO meeting is Tuesday, October 17, 2006, from 8:30 AM in EPN, at 6130 Executive Boulevard, Rockville, MD. The deadline for submission is August 31, 2006. See http://imaging.cancer.gov/programsandresources/specializedinitiatives/ICBIO for details.
CIP DCIDE PROGRAM
The Cancer Imaging Program of the NCI requests submissions for its Development of Clinical Imaging Drugs and Enhancers (DCIDE) initiative. The goal is the rapid movement of promising, novel cancer imaging enhancers or molecular probes from the laboratory to proof of principle clinical trials. See the web site for details.
The NIH Commons web site allows all NIH grantee organizations to interact with grants data, to check the status of grant applications, including viewing scores and summary statements when they are ready, and to submit progress reports on line, among a number of functions. Applicants and grants administrators should become familiar with the Commons.
SOCIETY OF NUCLEAR MEDICINE 53RD ANNUAL MEETING
San Diego, California, June 3-7, 2006. Look for CIP in booth 107.
WORLD CONFERENCE ON INTERVENTIONAL ONCOLOGY
June 12-16, 2006, Cernobbio, Italy
CARS 2006 COMPUTER ASSISTED RADIOLOGY AND SURGERY - 20TH INTERNATIONAL CONGRESS AND EXHIBITION
June 28 - July 1, 2006, Osaka Japan
SOCIETY OF MOLECULAR IMAGING
Hilton Waikoloa Village, Hawaii, Hawaii, August 30-September 2, 2006
IMAGING AS A BIOMARKER: STANDARDS FOR CHANGE MEASUREMENTS IN THERAPY
September 14 - 15, 2006, Gaithersburg, Maryland
INTERNATIONAL CONFERENCE ON QUALITY ASSURANCE AND NEW TECHNIQUES IN RADIATION MEDICINE (QANTRM)
November 13-15, 2006, Vienna, Austria. Organized by the International Atomic Energy Agency
November 26 - December 1, 2006, McCormick Place, Chicago, IL
17TH INTERNATIONAL SYMPOSIUM ON RADIOPHARMACEUTICAL SCIENCES
April 30 - May 4, 2007, Aachen, Germany
The Cancer Imaging Program at NCI has created this e-mail distribution list to notify interested people about funding opportunities and other issues related to imaging research. Its primary purpose is to call your attention to important, relevant information on NIH Web pages, or in the NIH Guide. Occasionally it may be used to clarify areas of confusion, or disseminate answers to frequently asked questions.
If you wish to remain on the list, no action is necessary. If you wish to be added to the list, please contact Dr Barbara Croft by return e-mail (email@example.com). Please include your complete mailing address, title, phone and fax numbers.
Cancer Imaging Program
Division of Cancer Treatment and Diagnosis, NCI
6130 Executive Boulevard - MSC-7412
Bethesda, MD 20892-7412
Tel: 301 496 9531
Fax: 301 480 3507